Agency Business briefs

Share this article:
Ignite Health named Hana Smetkova VP creative director for its Manhattan office. Smetkova joins the firm from CCG Metamedia, and before CCG she spent six years at Harrison & Star.  

Tonic Life Communications opened an office in Hong Kong, its first in Asia. The London-based healthcare PR shop, owned by Huntsworth Health, advertises itself as a “lifesciences to lifestyle” agency.

Schwartz Communications was named PR agency of record by Cerulean Pharma, a Cambridge, MA-based company which specializes in nanopharmaceuticals. The business will be handled out of the agency's Waltham, MA and London offices.

Spectrum announced it had won business from five clients in the first half of 2010: biotechs Alnylam Pharmaceuticals and Zeltia Group; The James Cancer Hospital at Ohio State University; healthcare immunization and wellness provider organization Maxim Health Systems; and rehab tech firm AlterG.

Interpublic said that its recent acquisition, UK shop Delaney Lund Knox Warren, will be known as DLKW Lowe and will serve as the UK hub for Lowe + Partners Worldwide.
Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Features

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?